Compound_ID |
Target |
Gene_Name |
Gene_ID |
Cancer |
Cell_lines |
IC50 Value |
EC50 Value |
ED50 Value |
GI50 Value |
Remarks |
References |
MMP-AC0095 |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
207 |
Ovarian adenocarcinoma |
OVCAR-3 |
- |
- |
- |
- |
The potential mechanism of acacetin in inhibiting VEGF expression, they showed that acacetin inhibited AKT activation. |
21893035 |
MMP-AC0095 |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
207 |
Ovarian Cancer |
A-2780 |
- |
- |
- |
- |
The potential mechanism of acacetin in inhibiting VEGF expression, they showed that acacetin inhibited AKT activation. |
21893035 |
MMP-AC0095 |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
1026 |
Lung adenocarcinoma |
A549 |
- |
- |
- |
- |
Increase in p21/WAF1 protein was apparent at 6 h and reached maximuminduction at 24 h in acacetin treated A549 cells. Moreover, the induction of p21/WAF1 was observed to be in a dose-dependent manner. Based on these data, we suggest that acacetin-mediated cell cycle arrest might operate through the induction of p21/WAF1 protein on a p53-dependent event in A549 cells. |
15246561 |
MMP-AC0095 |
HIF1A |
hypoxia inducible factor 1 |
3091 |
Ovarian adenocarcinoma |
OVCAR-3 |
- |
- |
- |
- |
Acacetin inhibited HIF-1alpha expression by increased HIF-1alpha protein degradation.The half-life of HIF-1alpha was 4.2 min and 5.2 min in OVCAR-3 and A2780 cells, respectively, in the presence of CHX alone, and was decreased to 2 min and 1.4 min, respectively with the treatment of acacetin. |
21893035 |
MMP-AC0095 |
HIF1A |
hypoxia inducible factor 1 |
3091 |
Ovarian Cancer |
A-2780 |
- |
- |
- |
- |
Acacetin inhibited HIF-1alphalpha expression by increased HIF-1alpha protein degradation.The half-life of HIF-1alphalpha was 4.2 min and 5.2 min in OVCAR-3 and A2780 cells, respectively, in the presence of CHX alone, and was decreased to 2 min and 1.4 min, respectively with the treatment of acacetin. |
21893035 |
MMP-AC0095 |
HIF1A |
hypoxia inducible factor 1 |
3091 |
Ovarian carcinoma |
OVCAR-3 |
- |
- |
- |
- |
The micro-vessel density was decreased by acacetin treatment to 50% of the control,showing that acacetin inhibited ovarian cancer cells-induced angiogenesis in vivo. Acacetin inhibited the levels of HIF-1alpha in tumor tissue samples |
21893035 |
MMP-AC0095 |
TP53 |
tumor protein p53 |
7157 |
Lung adenocarcinoma |
A549 |
- |
- |
- |
- |
The results showed a marked induction of p53 protein in the acacetin treated cells and a trend of dose-dependent manner. The upregulation of p53 by acacetin started to increase 6 h after being treated with acacetin, and maximum expression was observed at 12 h. |
15246561 |
MMP-AC0095 |
VEGFA |
vascular endothelial growth factor A |
7422 |
Ovarian adenocarcinoma |
OVCAR-3 |
- |
- |
- |
- |
Acacetin decreased VEGF transcriptional activation to 40% in OVCAR-3 cells, suggesting that this compound has a general effect to inhibit VEGF transcriptional activation in ovarian cancer cells. Acacetin at 10 然 and 20 然 greatly inhibited VEGF expression in OVCAR-3 cells. |
21893035 |
MMP-AC0095 |
VEGFA |
vascular endothelial growth factor A |
7422 |
Ovarian Cancer |
A-2780 |
- |
- |
- |
- |
Acacetin decreased VEGF transcriptional activation to 50% in A2780 cells, suggesting that this compound has a general effect to inhibit VEGF transcriptional activation in ovarian cancer cells. |
21893035 |
MMP-AC0095 |
VEGFA |
vascular endothelial growth factor A |
7422 |
Ovarian carcinoma |
OVCAR-3 |
- |
- |
- |
- |
Acacetin treatment inhibited tumor growth with 50% decrease of tumor weight when compared to that from the control group, indicating that acacetin suppresses tumor growth through impeding the angiogenesis. Acacetin inhibited the levels of VEGF expression in tumor tissue samples |
21893035 |